These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 1610324)

  • 41. The Results of Chemotherapy with Two Variants of Intravenous CMF in Patients with Early Stage Breast Carcinoma; Does Dose Density Matter?
    Salek R; Bayatmokhtari N; Homaei Shandiz F; ShahidSales S
    Breast J; 2016 Nov; 22(6):623-629. PubMed ID: 27540897
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial.
    International Breast Cancer Study Group (IBCSG)
    J Natl Cancer Inst; 2002 Jul; 94(14):1054-65. PubMed ID: 12122096
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Breast cancer recurrence dynamics following adjuvant CMF is consistent with tumor dormancy and mastectomy-driven acceleration of the metastatic process.
    Demicheli R; Miceli R; Moliterni A; Zambetti M; Hrushesky WJ; Retsky MW; Valagussa P; Bonadonna G
    Ann Oncol; 2005 Sep; 16(9):1449-57. PubMed ID: 15956037
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII.
    Crivellari D; Bonetti M; Castiglione-Gertsch M; Gelber RD; Rudenstam CM; Thürlimann B; Price KN; Coates AS; Hürny C; Bernhard J; Lindtner J; Collins J; Senn HJ; Cavalli F; Forbes J; Gudgeon A; Simoncini E; Cortes-Funes H; Veronesi A; Fey M; Goldhirsch A
    J Clin Oncol; 2000 Apr; 18(7):1412-22. PubMed ID: 10735888
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Postmastectomy adjuvant chemotherapy with or without radiation therapy in women with operable breast cancer and positive axillary lymph nodes: the Southeastern Cancer Study Group experience.
    Velez-Garcia E; Moore M; Vogel CL; Marcial V; Ketcham A; Bartolucci A; Liu C; Smalley R
    Breast Cancer Res Treat; 1983; 3 Suppl():S49-60. PubMed ID: 6367861
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Adjuvant CMF for node-negative and estrogen receptor-negative breast cancer patients.
    Zambetti M; Bonadonna G; Valagussa P; Daidone MG; Coradini D; Bignami P; Contesso G; Silvestrini R
    J Natl Cancer Inst Monogr; 1992; (11):77-83. PubMed ID: 1627434
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Paclitaxel and epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil for patients with stage IIIC breast cancer with ten or more involved axillary lymph nodes.
    Battelli N; Massacesi C; Braconi C; Pilone A; Manzione L; Dinota A; Cobelli S; Scanni A; Sturba F; Giacomini G; Morale D; Giorgi F; Tummarello D; Cascinu S
    Am J Clin Oncol; 2006 Aug; 29(4):380-4. PubMed ID: 16891866
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The CMF program for operable breast cancer with positive axillary nodes. Updated analysis on the disease-free interval, site of relapse and drug tolerance.
    Bonadonna G; Rossi A; Valagussa P; Banfi A; Veronesi U
    Cancer; 1977 Jun; 39(6 Suppl):2904-15. PubMed ID: 326384
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: preliminary results of the TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate).
    Schmid P; Untch M; Wallwiener D; Kossé V; Bondar G; Vassiljev L; Tarutinov V; Kienle E; Lüftner D; Possinger K;
    Anticancer Res; 2002; 22(4):2325-32. PubMed ID: 12174922
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil as adjuvant chemotherapy in breast cancer.
    Livi L; Saieva C; Borghesi S; De Luca Cardillo C; Scotti V; Mangoni M; Greto D; Cataliotti L; Paiar F; Bianchi S; Biti GP
    J Chemother; 2009 Nov; 21(5):558-65. PubMed ID: 19933048
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables.
    Ménard S; Valagussa P; Pilotti S; Gianni L; Biganzoli E; Boracchi P; Tomasic G; Casalini P; Marubini E; Colnaghi MI; Cascinelli N; Bonadonna G
    J Clin Oncol; 2001 Jan; 19(2):329-35. PubMed ID: 11208823
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial.
    ; Castiglione-Gertsch M; O'Neill A; Price KN; Goldhirsch A; Coates AS; Colleoni M; Nasi ML; Bonetti M; Gelber RD
    J Natl Cancer Inst; 2003 Dec; 95(24):1833-46. PubMed ID: 14679153
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A comparison of the outcomes of non-randomised chemotherapy regimens in node positive breast cancer.
    Kuru B; Camlibel M; Dinc S; Gulcelik MA; Atalay C; Alagol H
    J Exp Clin Cancer Res; 2005 Sep; 24(3):363-72. PubMed ID: 16270522
    [TBL] [Abstract][Full Text] [Related]  

  • 54. 3-year results of docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer: a pilot study.
    Ferreira Filho AF; Crown J; Cardoso F; Nogaret JM; Duffy K; Dolci S; Rowan S; O'Higgins N; Batter V; Paesmans M; Piccart MJ; Di Leo A
    Anticancer Res; 2002; 22(4):2471-6. PubMed ID: 12174946
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Combined chemotherapy and radiotherapy for patients with breast cancer and extensive nodal involvement.
    Ung O; Langlands AO; Barraclough B; Boyages J
    J Clin Oncol; 1995 Feb; 13(2):435-43. PubMed ID: 7844606
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Adjuvant chemotherapy with cyclophosphamide or CMF in premenopausal women with stage II breast cancer.
    Brincker H; Mouridsen HT; Andersen KW
    Breast Cancer Res Treat; 1983; 3(1):91-5. PubMed ID: 6347278
    [TBL] [Abstract][Full Text] [Related]  

  • 57. CMF (cyclophosphamide, methotrexate, 5-fluorouracil) versus CNF (cyclophosphamide, mitoxantrone, 5-fluorouracil) as adjuvant chemotherapy for stage II lymph-node positive breast cancer: results by demographic and clinical subgroups.
    Ron IG; Wigler N; Borovik R; Peretz T; Rizel S; Shani A; Brenner J; Farbstein H; Brenner HJ; Chaitchik S; Catane R; Inbar MJ
    Am J Clin Oncol; 2002 Oct; 25(5):520-2. PubMed ID: 12393997
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Controlled trial of adjuvant chemotherapy with cyclophosphamide, methotrexate, and fluorouracil for breast cancer.
    Howell A; Bush H; George WD; Howat JM; Crowther D; Sellwood RA; Rubens RD; Hayward JL; Bulbrook RD; Fentiman IS
    Lancet; 1984 Aug; 2(8398):307-11. PubMed ID: 6146861
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The 5-year results of a randomized trial of adjuvant radiation therapy after chemotherapy in breast cancer patients treated with mastectomy.
    Griem KL; Henderson IC; Gelman R; Ascoli D; Silver B; Recht A; Goodman RL; Hellman S; Harris JR
    J Clin Oncol; 1987 Oct; 5(10):1546-55. PubMed ID: 3309196
    [TBL] [Abstract][Full Text] [Related]  

  • 60. 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study.
    Bonadonna G; Moliterni A; Zambetti M; Daidone MG; Pilotti S; Gianni L; Valagussa P
    BMJ; 2005 Jan; 330(7485):217. PubMed ID: 15649903
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.